Prevention of postmenopausal bone loss with minimal uterine bleeding using low dose continuous estrogen/progestin therapy: A 2-year prospective study

Maturitas

Volumn 27, Issue 1, 1997, Pages 69-76

  Mizunuma, Hideki ^a   Okano, Hiroya ^a   Soda, Masayuki ^a   Kagami, Issei ^a   Miyamoto, Sumitka ^a   Tokizawa, Toshiya ^a   Honjo, Shigeichirou ^a   Ibuki, Yoshito ^a  

^a GUNMA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ESTROGEN; GESTAGEN;

ADULT; ARTICLE; BONE DENSITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HORMONE SUBSTITUTION; HUMAN; MAJOR CLINICAL STUDY; POSTMENOPAUSE OSTEOPOROSIS; RADIODIAGNOSIS; RANDOMIZED CONTROLLED TRIAL;

BONE DENSITY; DOSE-RESPONSE RELATIONSHIP, DRUG; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE; MIDDLE AGED; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTERONE CONGENERS; PROSPECTIVE STUDIES; UTERINE HEMORRHAGE;

EID: 0030918024     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0378-5122(97)01110-9     Document Type: Article

References (22)

1. Genant HK, Cann CE, Ettínger B, Gordan GS. Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 1982; 97: 699-705.
2. Lindsay R, Hart M, Clark DM. The minimum effective dose of estrogen for prevention of postmenopausal bone loss. Obstet Gynecol 1984; 63: 759-763.
3. Physician's Resource manual on osteoporosis. A decisionmaking guide. National Osteoporosis Foundation. Co. Medica Inc., 1987.
4. Conference report. Consensus development conference: prophylaxis and treatment of osteoporosis. Am J Med 1991; 90: 107-110.
5. Geola FL, Frumar AM, Tataryn IV, Lu KH, Hershman JM, Eggena P, Sambhi MP, Judd HL. Biological effects of various doses of conjugated equine estrogens in postmenopausal women. J Clin Endocrinol Metab 1980; 51: 620-625.
6. Hillard TC, Siddle NC, Whitehead MI, Fraser DI, Pryse-Davies J. Continuous combined conjugated equine estrogen-progestogen therapy: effects and endometrial histologic diagnosis. Am J Obstet Gynecol 1992; 167: 1-7.
7. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Obstet Gynecol 1994; 83: 686-692.
8. Soda M, Mizunuma H, Honjo S, Okano H, Ibuki Y, Igarashi M. Pre-and postmenopausal bone mineral density of the spine and proximal femur in Japanese women assessed by dual-energy X-ray absorptiometry: a cross-sectional study. J Bone Miner Res 1993; 8: 183-189.
9. Kalender WA, Klotz E, Suess C. Vertebral bone mineral analysis: an integrated approach with CT. Radiology 1987; 164: 419-423.
10. Parfitt AM. The physiological and clinical significance of bone histomorphometric date. In: Recker RR (ed). Bone Histomorphometry. Techniques and Interpretation. CRC Press. Boca Raton, FL. pp 143-223, 1982.
11. Nilas L, Borg J, Gotfredsen A, Christiansen CA. Comparison of single-and dual-photon absorptiometry in postmenopausal bone mineral loss. J Nucl Med 1985; 26: 1257-1262.
12. Ettinger B, Genant HK, Cann CE. Postmenopausal bone loss is prevented by treatment with low-dosage estrogen with calcium. Ann Int Med 1987; 106: 40-45.
13. Webber CE, Blake JM, Chambers LF, Roberts JG. Effects of 2 years of hormone replacement upon bone mass, serum lipids and lipoproteins. Maturitas 1994; 19: 13-23.
14. Gallagher JC, Kable WT, Goldgar D. Effect of progestin therapy on cortical and trabecular bone: comparison with estrogen. Am J Med 1991; 90: 171-178.
15. Paterson MEL, Sturdee DW, Moore B, Whitehead TP. The effects of various regimens of hormone therapy on serum cholesterol and triglyceride concentrations in postmenopausal women. Br J Obstet Gynecol 1980; 87: 552-560.
16. Wahl P, Waiden CA, Knopp R, Hoover J, Wallace R, Heiss G, Rifkind B. Effect of estrogen/progestin potency on lipid/lipoprotein cholesterol. New Engl J Med 1983; 308: 862-867.
17. MacLennan AH, MacLennan A, Wenzel S, Chambers HM, Eckert K. Continuous low-dose oestrogen and progestogen hormone replacement therapy: a randomised trial. Med J Aust 1993; 19: 102-106.
18. Weinstein L. Efficacy of a continuous estrogen-progestin regimen in the menopausal patient. Obstet Gynecol 1987; 69: 929-932.
19. Leather AT, Savvas M, Studd JW. Endometrial histology and bleeding paterns after 8 years of continuous combined estrogen and progestogen therapy. Obstet Gynecol 1991; 78: 1008-1010.
20. Goodman L, Awwad J, Marc K, Schiff I. Continuous combined hormonal replacement therapy and the risk of endometrial cancer. Menopause: J N Am Menopause Soc 1994; 1: 57-59.
21. Gambrell RD Jr, McDonough PG. (Letter) The 'red queen' and endometrial hyperplasia. Fertil Steril 1994; 61: 401-402.
22. Grey AB, Cundy TF, Reid IR. Continuous combined oestrogen/progestin therapy is well tolerated and increases bone density at the hip and spine in post-menopausal osteoporosis. Clin Endocrinol 1994; 40: 671-677.